Patrick Colin
Corporate Officer/Principal at Quebec Order of Pharmacists
Profile
Patrick Colin was the founder of gIcare Pharma, Inc. founded in 2011, where he held the title of Chief Development Officer.
Currently, he is a Professor at the University of Montréal, Université Laval, and a Member of the Quebec Order of Pharmacists.
Previously, he held the position of Principal at Bristol Myers Squibb Co., Vice President-Research & Development at Aptalis Pharma Canada ULC, and Chief Development Officer & Senior Vice President at Verlyx Pharma, Inc. Dr. Colin received his undergraduate degree in 1980 and his doctorate in 1987 from the University of Montréal.
Patrick Colin active positions
| Companies | Position | Start |
|---|---|---|
Quebec Order of Pharmacists
 Quebec Order of Pharmacists Miscellaneous Commercial ServicesCommercial Services Quebec Order of Pharmacists operates association for pharmacists. It recognizes the public''s right to information and favors transparent and proactive communication, imbued with the values of humanism and integrity. The company is headquartered in Montreal, Canada. | Corporate Officer/Principal | - |
| University of Montréal | Corporate Officer/Principal | - |
| Université Laval | Corporate Officer/Principal | - |
Former positions of Patrick Colin
| Companies | Position | End |
|---|---|---|
Verlyx Pharma, Inc.
 Verlyx Pharma, Inc. Pharmaceuticals: MajorHealth Technology Verlyx Pharma, Inc. develops cancer treatments. It is a pharmaceutical company involved in the development of liver-targeting therapeutic agents for the treatment of liver diseases. The firm’s product VLX103, is a proprietary form of pentamidine that combines hepatoselective and hepatoprotective properties. The company was founded in 1999 by Terry Chow and David Griller and is headquartered in Montréal, Canada. | Corporate Officer/Principal | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
gIcare Pharma, Inc.
 gIcare Pharma, Inc. Pharmaceuticals: MajorHealth Technology gIcare Pharma, Inc. develops gastrointestinal drugs. It develops orally-administered drug GIC-1001 which provides colonic analgesia. The company was founded by Patrick Colin and Maxime Ranger in 2011 and is headquartered in Montreal, Canada. | Founder | - |
Aptalis Pharma Canada ULC
 Aptalis Pharma Canada ULC Pharmaceuticals: MajorHealth Technology Aptalis Pharma Canada ULC provided pharmaceutical products. The company was founded in 1982 and was headquartered in Mount Saint-Hilaire, Canada. | Chief Tech/Sci/R&D Officer | - |
Training of Patrick Colin
| University of Montréal | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private companies | 4 |
|---|---|
Aptalis Pharma Canada ULC
Aptalis Pharma Canada ULC Pharmaceuticals: MajorHealth Technology Aptalis Pharma Canada ULC provided pharmaceutical products. The company was founded in 1982 and was headquartered in Mount Saint-Hilaire, Canada. | Health Technology |
Quebec Order of Pharmacists
Quebec Order of Pharmacists Miscellaneous Commercial ServicesCommercial Services Quebec Order of Pharmacists operates association for pharmacists. It recognizes the public''s right to information and favors transparent and proactive communication, imbued with the values of humanism and integrity. The company is headquartered in Montreal, Canada. | Commercial Services |
gIcare Pharma, Inc.
gIcare Pharma, Inc. Pharmaceuticals: MajorHealth Technology gIcare Pharma, Inc. develops gastrointestinal drugs. It develops orally-administered drug GIC-1001 which provides colonic analgesia. The company was founded by Patrick Colin and Maxime Ranger in 2011 and is headquartered in Montreal, Canada. | Health Technology |
Verlyx Pharma, Inc.
Verlyx Pharma, Inc. Pharmaceuticals: MajorHealth Technology Verlyx Pharma, Inc. develops cancer treatments. It is a pharmaceutical company involved in the development of liver-targeting therapeutic agents for the treatment of liver diseases. The firm’s product VLX103, is a proprietary form of pentamidine that combines hepatoselective and hepatoprotective properties. The company was founded in 1999 by Terry Chow and David Griller and is headquartered in Montréal, Canada. | Health Technology |
- Stock Market
- Insiders
- Patrick Colin